Rational design of competitive prolactin/growth hormone receptor antagonists

Journal of Mammary Gland Biology and Neoplasia

Volumn 13, Issue 1, 2008, Pages 105-117

  Tallet, Estelle ^a,b   Rouet, Vincent ^a,b   Jomain, Jean Baptiste ^a,b   Kelly, Paul A ^a,b   Bernichtein, Sophie ^a,b   Goffin, Vincent ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

B2036; G120R hGH; G129R hPRL; Pegvisomant; 1 9 G129R hPRL

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOSTATIN; G 129R; GLYCINE; GROWTH HORMONE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; PEGVISOMANT; PROLACTIN; PROLACTIN RECEPTOR; PROLACTIN RECEPTOR ANTAGONIST; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; BINDING SITE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; GENE MUTATION; GROWTH REGULATION; HORMONE INHIBITION; HUMAN; HYPERPROLACTINEMIA; METASTASIS POTENTIAL; MONOTHERAPY; MUTATIONAL ANALYSIS; NONHUMAN; PATHOGENESIS; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; SURVIVAL TIME;

EID: 40249089818     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-008-9066-8     Document Type: Review

References (99)

1. 1. MP Gillam ME Molitch G Lombardi A Colao 2006 Advances in the treatment of prolactinomas Endocr Rev. 27 485 534 16705142 10.1210/er.2005-9998 1:CAS:528:DC%2BD28XpvVelurY%3D Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534.
2. 2. CW Welsch H Nagasawa 1977 Prolactin and murine mammary tumorigenesis: a review Cancer Res. 37 951 963 191183 1:CAS:528:DyaE2sXhsFegt7k%3D Welsch CW, Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res. 1977;37:951–63.
3. 3. V Goffin S Bernichtein P Touraine PA Kelly 2005 Development and potential clinical uses of human prolactin receptor antagonists Endocr Rev. 26 400 422 15814850 10.1210/er.2004-0016 1:CAS:528:DC%2BD2MXltVWru7k%3D Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev. 2005;26:400–22.
4. 4. CV Clevenger PA Furth SE Hankinson LA Schuler 2003 The role of prolactin in mammary carcinoma Endocr Rev. 24 1 27 12588805 10.1210/er.2001-0036 1:CAS:528:DC%2BD3sXhslOgsb8%3D Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24:1–27.
5. 5. BK Vonderhaar 1999 Prolactin involvement in breast cancer Endocr Relat Cancer. 6 389 404 10516853 10.1677/erc.0.0060389 1:CAS:528:DyaK1MXmsVOmt7Y%3D Vonderhaar BK. Prolactin involvement in breast cancer. Endocr Relat Cancer. 1999;6:389–404.
6. 6. N Ben Jonathan R Hnasko 2001 Dopamine as a prolactin (PRL) inhibitor Endocr Rev. 22 724 763 11739329 10.1210/er.22.6.724 1:CAS:528:DC%2BD38XltlOhug%3D%3D Ben Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724–63.
7. 7. N Ben-Jonathan JL Mershon DL Allen RW Steinmetz 1996 Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects Endocr Rev. 17 639 669 8969972 10.1210/er.17.6.639 1:CAS:528:DyaK2sXmtVamtg%3D%3D Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17:639–69.
8. 8. ME Molitch 2002 Medical management of prolactin-secreting pituitary adenomas Pituitary. 5 55 65 12675502 10.1023/A:1022375429083 1:CAS:528:DC%2BD3sXhtVOlurg%3D Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary. 2002;5:55–65.
9. 9. BM Arafah MP Nasrallah 2001 Pituitary tumors: pathophysiology, clinical manifestations and management Endocr Relat Cancer. 8 287 305 11733226 10.1677/erc.0.0080287 1:STN:280:DC%2BD3MnoslWjsQ%3D%3D Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer. 2001;8:287–305.
10. 10. D Fritze W Queisser H Schmid M Kaufmann B Massner M Westerhausen 1986 Prospective randomized trial concerning hyper-and normoprolactinemia and the use of bromoergocryptine in patients with metastatic breast cancer Onkologie. 9 305 312 2950359 1:STN:280:DyaL2s7ksFGlug%3D%3D 10.1159/000216041 Fritze D, Queisser W, Schmid H, Kaufmann M, Massner B, Westerhausen M, et al. Prospective randomized trial concerning hyper-and normoprolactinemia and the use of bromoergocryptine in patients with metastatic breast cancer. Onkologie. 1986;9:305–12.
11. 11. J Bonneterre L Mauriac B Weber H Roche P Fargeot M Tubiana-Hulin 1988 Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial Eur J Cancer Clin Oncol. 24 1851 1853 3065085 10.1016/0277-5379(88)90097-1 1:STN:280:DyaL1M7itVylug%3D%3D Bonneterre J, Mauriac L, Weber B, Roche H, Fargeot P, Tubiana-Hulin M, et al. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. Eur J Cancer Clin Oncol. 1988;24:1851–3.
12. 12. J Horti WD Figg B Weinberger D Kohler O Sartor 1998 A phase II study of bromocriptine in patients with androgen-independent prostate cancer Oncol Rep. 5 893 896 9625840 1:CAS:528:DyaK1cXkt1ehtb8%3D Horti J, Figg WD, Weinberger B, Kohler D, Sartor O. A phase II study of bromocriptine in patients with androgen-independent prostate cancer. Oncol Rep. 1998;5:893–6.
13. 13. CV Clevenger 2003 Nuclear localization and function of polypeptide ligands and their receptors: a new paradigm for hormone specificity within the mammary gland? Breast Cancer Res. 5 181 187 12817988 10.1186/bcr601 1:CAS:528:DC%2BD3sXkvVKkur8%3D Clevenger CV. Nuclear localization and function of polypeptide ligands and their receptors: a new paradigm for hormone specificity within the mammary gland? Breast Cancer Res. 2003;5:181–7.
14. 14. N Ben Jonathan K Liby M McFarland M Zinger 2002 Prolactin as an autocrine/paracrine growth factor in human cancer Trends Endocrinol Metab. 13 245 250 12128285 10.1016/S1043-2760(02)00603-3 1:CAS:528:DC%2BD38XlsVOktr8%3D Ben Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab. 2002;13:245–50.
15. 15. M Llovera P Touraine PA Kelly V Goffin 2000 Involvement of prolactin in breast cancer: redefining the molecular targets Exp Gerontol. 35 41 51 10705038 10.1016/S0531-5565(99)00078-9 1:CAS:528:DC%2BD3cXhsFGqt7c%3D Llovera M, Touraine P, Kelly PA, Goffin V. Involvement of prolactin in breast cancer: redefining the molecular targets. Exp Gerontol. 2000;35:41–51.
16. 16. TA Rose-Hellekant LM Arendt MD Schroeder K Gilchrist EP Sandgren LA Schuler 2003 Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice Oncogene. 22 4664 4674 12879011 10.1038/sj.onc.1206619 1:CAS:528:DC%2BD3sXls1Gjt7g%3D Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene. 2003;22:4664–74.
17. 17. P Touraine JF Martini B Zafrani JC Durand F Labaille C Malet 1998 Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues J Clin Endocrinol Metab. 83 667 674 9467590 10.1210/jc.83.2.667 1:CAS:528:DyaK1cXpvFeitA%3D%3D Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab. 1998;83:667–74.
18. 18. H Li TJ Ahonen K Alanen J Xie MJ LeBaron TG Pretlow 2004 Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade Cancer Res. 64 4774 4782 15256446 10.1158/0008-5472.CAN-03-3499 1:CAS:528:DC%2BD2cXls1OmsLc%3D Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res. 2004;64:4774–82.
19. 19. J Kindblom K Dillner L Sahlin F Robertson C Ormandy J Tornell 2003 Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin Endocrinology. 144 2269 2278 12746285 10.1210/en.2002-0187 1:CAS:528:DC%2BD3sXktFehtb4%3D Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J, et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology. 2003;144:2269–78.
20. 20. C Manhes C Kayser P Bertheau B Kelder JJ Kopchick PA Kelly 2006 Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma J Endocrinol 190 271 285 16899561 10.1677/joe.1.06829 1:CAS:528:DC%2BD28Xpt1Wjt7g%3D Manhes C, Kayser C, Bertheau P, Kelder B, Kopchick JJ, Kelly PA, et al. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. J Endocrinol 2006;190:271–85.
21. 21. M Zinger M McFarland N Jonathan Ben 2003 Prolactin expression and secretion by human breast glandular and adipose tissue explants J Clin Endocrinol Metab. 88 689 696 12574200 10.1210/jc.2002-021255 1:CAS:528:DC%2BD3sXhtlCht74%3D Zinger M, McFarland M, Ben Jonathan N. Prolactin expression and secretion by human breast glandular and adipose tissue explants. J Clin Endocrinol Metab. 2003;88:689–96.
22. 22. I Manfroid WC De Van A Baudhuin JA Martial M Muller 2005 EGF stimulates Pit-1 independent transcription of the human prolactin pituitary promoter in human breast cancer SK-BR-3 cells through its proximal AP-1 response element Mol Cell Endocrinol. 229 127 139 15607537 10.1016/j.mce.2004.08.009 1:CAS:528:DC%2BD2cXhtVyqs7jF Manfroid I, Van De WC, Baudhuin A, Martial JA, Muller M. EGF stimulates Pit-1 independent transcription of the human prolactin pituitary promoter in human breast cancer SK-BR-3 cells through its proximal AP-1 response element. Mol Cell Endocrinol. 2005;229:127–39.
23. 23. A Baudhuin I Manfroid WC De Van JA Martial M Muller 2002 Transcription of the human prolactin gene in mammary cells Ann N Y Acad Sci. 973 454 458 12485910 1:CAS:528:DC%2BD38Xps1yitbg%3D Baudhuin A, Manfroid I, Van De WC, Martial JA, Muller M. Transcription of the human prolactin gene in mammary cells. Ann N Y Acad Sci. 2002;973:454–8.
24. 24. HC Mertani T Zhu EL Goh KO Lee G Morel PE Lobie 2001 Autocrine human growth hormone (hGH) regulation of human mammary carcinoma cell gene expression. Identification of CHOP as a mediator of hGH stimulated human mammary carcinoma cell survival J Biol Chem 276 21464 21475 11297545 10.1074/jbc.M100437200 1:CAS:528:DC%2BD3MXksFGlurk%3D Mertani HC, Zhu T, Goh EL, Lee KO, Morel G, Lobie PE. Autocrine human growth hormone (hGH) regulation of human mammary carcinoma cell gene expression. Identification of CHOP as a mediator of hGH stimulated human mammary carcinoma cell survival. J Biol Chem 2001;276:21464–75.
25. 25. HC Mertani T Garcia-Caballero A Lambert F Gerard C Palayer JM Boutin 1998 Cellular expression of growth hormone and prolactin receptors in human breast disorders Int J Cancer. 79 202 211 9583737 10.1002/(SICI)1097-0215(19980417)79:2<202::AID-IJC17>3.0.CO;2-B 1:CAS:528:DyaK1MXksl2ku70%3D Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer. 1998;79:202–11.
26. 26. S Mukhina HC Mertani K Guo KO Lee PD Gluckman PE Lobie 2004 Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone Proc Natl Acad Sci U S A. 101 15166 15171 15353581 10.1073/pnas.0405881101 1:CAS:528:DC%2BD2cXpsVSgsbY%3D Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci U S A. 2004;101:15166–71.
27. 27. KK Kaulsay T Zhu W Bennett K Lee PE Lobie 2001 The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor Endocrinology. 142 767 777 11159849 10.1210/en.142.2.767 1:CAS:528:DC%2BD3MXhtFSrt7w%3D Kaulsay KK, Zhu T, Bennett W, Lee K, Lobie PE. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology. 2001;142:767–77.
28. 28. MJ Waters JL Barclay 2007 Does growth hormone drive breast and other cancers? Endocrinology. 148 4533 4535 17876033 10.1210/en.2007-0855 1:CAS:528:DC%2BD2sXhtFWls73O Waters MJ, Barclay JL. Does growth hormone drive breast and other cancers? Endocrinology. 2007;148:4533–5.
29. 29. K Teilum JC Hoch V Goffin S Kinet JA Martial BB Kragelund 2005 Solution structure of human prolactin J Mol Biol. 351 810 823 16045928 10.1016/j.jmb.2005.06.042 1:CAS:528:DC%2BD2MXntVGmt70%3D Teilum K, Hoch JC, Goffin V, Kinet S, Martial JA, Kragelund BB. Solution structure of human prolactin. J Mol Biol. 2005;351:810–23.
30. 30. AM Vos De M Ultsch AA Kossiakoff 1992 Human growth hormone and extracellular domain of its receptor: crystal structure of the complex Science. 255 306 312 1549776 10.1126/science.1549776 De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255:306–12.
31. 31. ND Horseman LY Yu-Lee 1994 Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines Endocr Rev. 15 627 649 7843070 10.1210/er.15.5.627 1:CAS:528:DyaK2MXit1eitrg%3D Horseman ND, Yu-Lee LY. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr Rev. 1994;15:627–49.
32. 32. PA Kelly J Djiane D Banville S Ali M Edery M Rozakis 1991 The growth hormone/prolactin receptor gene family N Maclean Oxford surveys on eukaryotic genes Oxford University Press London 29 50 Kelly PA, Djiane J, Banville D, Ali S, Edery M, Rozakis M. The growth hormone/prolactin receptor gene family. In: Maclean N, editor. Oxford surveys on eukaryotic genes. London: Oxford University Press; 1991. p. 29–50.
33. 33. JM Boutin C Jolicoeur H Okamura J Gagnon M Edery M Shirota 1988 Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family Cell. 53 69 77 2832068 10.1016/0092-8674(88)90488-6 1:CAS:528:DyaL1cXlsVelsr0%3D Boutin JM, Jolicoeur C, Okamura H, Gagnon J, Edery M, Shirota M, et al. Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. Cell. 1988;53:69–77.
34. 34. JA Wells AM Vos De 1996 Hematopoietic receptor complexes Annu Rev Biochem. 65 609 634 8811191 10.1146/annurev.bi.65.070196.003141 1:CAS:528:DyaK28XktFamur8%3D Wells JA, De Vos AM. Hematopoietic receptor complexes. Annu Rev Biochem. 1996;65:609–34.
35. 35. PA Elkins HW Christinger Y Sandowski E Sakal A Gertler AM Vos De 2000 Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor Nat Struct Biol. 7 808 815 10966654 10.1038/79047 1:CAS:528:DC%2BD3cXmsFWksrk%3D Elkins PA, Christinger HW, Sandowski Y, Sakal E, Gertler A, De Vos AM, et al. Ternary complex between placental lactogen and the extracellular domain of the prolactin receptor. Nat Struct Biol. 2000;7:808–15.
36. 36. G Fuh BC Cunningham R Fukunaga S Nagata DV Goeddel JA Wells 1992 Rational design of potent antagonists to the human growth hormone receptor Science. 256 1677 1680 1535167 10.1126/science.256.5064.1677 1:CAS:528:DyaK38Xks1egt7w%3D Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science. 1992;256:1677–80.
37. 37. V Goffin KT Shiverick PA Kelly JA Martial 1996 Sequence–function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals Endocr Rev. 17 385 410 8854051 10.1210/er.17.4.385 1:CAS:528:DyaK28Xltl2mt70%3D Goffin V, Shiverick KT, Kelly PA, Martial JA. Sequence–function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev. 1996;17:385–410.
38. 38. MJ Waters HN Hoang DP Fairlie RA Pelekanos RJ Brown 2006 New insights into growth hormone action J Mol Endocrinol. 36 1 7 16461922 10.1677/jme.1.01933 1:CAS:528:DC%2BD28XhvFWmtLk%3D Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ. New insights into growth hormone action. J Mol Endocrinol. 2006;36:1–7.
39. 39. RJ Brown JJ Adams RA Pelekanos Y Wan WJ McKinstry K Palethorpe 2005 Model for growth hormone receptor activation based on subunit rotation within a receptor dimer Nat Struct Mol Biol. 12 814 821 16116438 10.1038/nsmb977 1:CAS:528:DC%2BD2MXpslaqtLo%3D Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol. 2005;12:814–21.
40. 40. AM Qazi CH Tsai-Morris ML Dufau 2006 Ligand-independent homo-and hetero-dimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization Mol Endocrinol. 20 1912 1923 16556730 10.1210/me.2005-0291 1:CAS:528:DC%2BD28XnvFajsLw%3D Qazi AM, Tsai-Morris CH, Dufau ML. Ligand-independent homo-and hetero-dimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Mol Endocrinol. 2006;20:1912–23.
41. 41. SL Gadd CV Clevenger 2006 Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications Mol Endocrinol. 20 2734 2746 16840534 10.1210/me.2006-0114 1:CAS:528:DC%2BD28XhtFymsb7N Gadd SL, Clevenger CV. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol. 2006;20:2734–46.
42. 42. D Tan DA Johnson W Wu L Zeng YH Chen WY Chen 2005 Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo-and hetero-pairs of long and short human prolactin receptors in living human cells Mol Endocrinol. 19 1291 1303 15695371 10.1210/me.2004-0304 1:CAS:528:DC%2BD2MXktFentrc%3D Tan D, Johnson DA, Wu W, Zeng L, Chen YH, Chen WY, et al. Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo-and hetero-pairs of long and short human prolactin receptors in living human cells. Mol Endocrinol. 2005;19:1291–303.
43. 43. JR James MI Oliveira AM Carmo A Iaboni SJ Davis 2006 A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer Nat Methods. 3 1001 1006 17086179 10.1038/nmeth978 1:CAS:528:DC%2BD28Xht1Wqu77P James JR, Oliveira MI, Carmo AM, Iaboni A, Davis SJ. A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer. Nat Methods. 2006;3:1001–6.
44. 44. SL Gadd CV Clevenger 2006 Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications Mol Endocrinol. 20 2734 2746 16840534 10.1210/me.2006-0114 1:CAS:528:DC%2BD28XhtFymsb7N Gadd SL, Clevenger CV. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol. 2006;20:2734–46.
45. 45. WY Chen DC Wight BV Mehta TE Wagner JJ Kopchick 1991 Glycine 119 of bovine growth hormone is critical for growth-promoting activity Mol Endocrinol. 5 1845 1852 1791834 1:CAS:528:DyaK3sXhvVeltrs%3D Chen WY, Wight DC, Mehta BV, Wagner TE, Kopchick JJ. Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol. 1991;5:1845–52.
46. 46. WY Chen DC Wight TE Wagner JJ Kopchick 1990 Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice Proc Natl Acad Sci U S A. 87 5061 5065 2367524 10.1073/pnas.87.13.5061 1:CAS:528:DyaK3cXkvFaktrc%3D Chen WY, Wight DC, Wagner TE, Kopchick JJ. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci U S A. 1990;87:5061–5.
47. 47. JJ Kopchick C Parkinson EC Stevens PJ Trainer 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly Endocr Rev. 23 623 646 12372843 10.1210/er.2001-0022 1:CAS:528:DC%2BD38XosVejsbk%3D Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002;23:623–46.
48. 48. T Clackson MH Ultsch JA Wells AM Vos De 1998 Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity J Mol Biol. 277 1111 1128 9571026 10.1006/jmbi.1998.1669 1:CAS:528:DyaK1cXivF2nurc%3D Clackson T, Ultsch MH, Wells JA, De Vos AM. Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol. 1998;277:1111–28.
49. 49. G Fuh P Colosi WI Wood JA Wells 1993 Mechanism-based design of prolactin receptor antagonists J Biol Chem. 268 5376 5381 8449901 1:CAS:528:DyaK3sXhvVelu7o%3D Fuh G, Colosi P, Wood WI, Wells JA. Mechanism-based design of prolactin receptor antagonists. J Biol Chem. 1993;268:5376–81.
50. 50. G Fuh JA Wells 1995 Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines J Biol Chem. 270 13133 13137 7768908 10.1074/jbc.270.22.13133 1:CAS:528:DyaK2MXmtV2itbw%3D Fuh G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem. 1995;270:13133–7.
51. 51. KK Kaulsay HC Mertani J Tornell G Morel KO Lee PE Lobie 1999 Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone Exp Cell Res. 250 35 50 10388519 10.1006/excr.1999.4492 1:CAS:528:DyaK1MXktV2ksLc%3D Kaulsay KK, Mertani HC, Tornell J, Morel G, Lee KO, Lobie PE. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp Cell Res. 1999;250:35–50.
52. 52. RJ Ross KC Leung M Maamra W Bennett N Doyle MJ Waters 2001 Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer J Clin Endocrinol Metab. 86 1716 1723 11297608 10.1210/jc.86.4.1716 1:CAS:528:DC%2BD3MXivVCks7s%3D Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab. 2001;86:1716–23.
53. 53. V Goffin S Bernichtein O Carrière WF Bennett JJ Kopchick PA Kelly 1999 The human growth hormone antagonist B2036 does not interact with the prolactin receptor Endocrinology. 140 3853 3856 10433247 10.1210/en.140.8.3853 1:CAS:528:DyaK1MXkslKqsLk%3D Goffin V, Bernichtein S, Carrière O, Bennett WF, Kopchick JJ, Kelly PA. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology. 1999;140:3853–6.
54. 54. S Bernichtein C Kayser K Dillner S Moulin JJ Kopchick JA Martial 2003 Development of pure prolactin receptor antagonists J Biol Chem. 278 35988 35999 12824168 10.1074/jbc.M305687200 1:CAS:528:DC%2BD3sXnt1aqtb0%3D Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, et al. Development of pure prolactin receptor antagonists. J Biol Chem. 2003;278:35988–99.
55. 55. B Bernat G Pal M Sun AA Kossiakoff 2003 Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization Proc Natl Acad Sci U S A. 100 952 957 12552121 10.1073/pnas.0235023100 1:CAS:528:DC%2BD3sXhtF2gsLo%3D Bernat B, Pal G, Sun M, Kossiakoff AA. Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization. Proc Natl Acad Sci U S A. 2003;100:952–7.
56. 56. ST Walsh LM Jevitts JE Sylvester AA Kossiakoff 2003 Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization Protein Sci. 12 1960 1970 12930995 10.1110/ps.03133903 1:CAS:528:DC%2BD3sXmvVehs78%3D Walsh ST, Jevitts LM, Sylvester JE, Kossiakoff AA. Site2 binding energetics of the regulatory step of growth hormone-induced receptor homodimerization. Protein Sci. 2003;12:1960–70.
57. 57. J Gent EM Den Van P Kerkhof van GJ Strous 2003 Dimerization and signal transduction of the growth hormone receptor Mol Endocrinol. 17 967 975 12576487 10.1210/me.2002-0261 1:CAS:528:DC%2BD3sXktFKnurc%3D Gent J, Van Den EM, van Kerkhof P, Strous GJ. Dimerization and signal transduction of the growth hormone receptor. Mol Endocrinol. 2003;17:967–75.
58. 58. PA Harding X Wang S Okada WY Chen W Wan JJ Kopchick 1996 Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization J Biol Chem. 271 6708 6712 8636090 10.1074/jbc.271.12.6708 1:CAS:528:DyaK28XhvVyis7g%3D Harding PA, Wang X, Okada S, Chen WY, Wan W, Kopchick JJ. Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization. J Biol Chem. 1996;271:6708–12.
59. 59. JB Jomain E Tallet I Broutin S Hoos J Agthoven Van A Ducruix 2007 Structural and thermodynamical bases for the design of pure prolactin receptor antagonists. X-ray structure of Del1–9-G129R-hPRL J Biol Chem. 282 33118 33131 17785459 10.1074/jbc.M704364200 1:CAS:528:DC%2BD2sXht1Clur%2FE Jomain JB, Tallet E, Broutin I, Hoos S, Van Agthoven J, Ducruix A, et al. Structural and thermodynamical bases for the design of pure prolactin receptor antagonists. X-ray structure of Del1–9-G129R-hPRL. J Biol Chem. 2007;282:33118–31.
60. 60. S Bernichtein S Kinet S Jeay M Madern JA Martial PA Kelly 2001 S179D-hPRL, a pseudo-phosphorylated human prolactin analog, is an agonist and not an antagonist Endocrinology. 142 3950 3963 11517174 10.1210/en.142.9.3950 1:CAS:528:DC%2BD3MXmsFSgsL4%3D Bernichtein S, Kinet S, Jeay S, Madern M, Martial JA, Kelly PA, et al. S179D-hPRL, a pseudo-phosphorylated human prolactin analog, is an agonist and not an antagonist. Endocrinology. 2001;142:3950–63.
61. 61. S Kinet S Bernichtein PA Kelly JA Martial V Goffin 1999 Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites J Biol Chem. 274 26033 26043 10473550 10.1074/jbc.274.37.26033 1:CAS:528:DyaK1MXmtVKmt7o%3D Kinet S, Bernichtein S, Kelly PA, Martial JA, Goffin V. Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites. J Biol Chem. 1999;274:26033–43.
62. 62. V Goffin I Struman V Mainfroid S Kinet JA Martial 1994 Evidence for a second receptor binding site on human prolactin J Biol Chem. 269 32598 32606 7798264 1:CAS:528:DyaK2cXmvFaqtbY%3D Goffin V, Struman I, Mainfroid V, Kinet S, Martial JA. Evidence for a second receptor binding site on human prolactin. J Biol Chem. 1994;269:32598–606.
63. 63. A Mode P Tollet T Wells DF Carmignac RG Clark WY Chen 1996 The human growth hormone (hGH) antagonist G120RhGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor Endocrinology. 137 447 454 8593788 10.1210/en.137.2.447 1:CAS:528:DyaK28XntVCisw%3D%3D Mode A, Tollet P, Wells T, Carmignac DF, Clark RG, Chen WY, et al. The human growth hormone (hGH) antagonist G120RhGH does not antagonize GH in the rat, but has paradoxical agonist activity, probably via the prolactin receptor. Endocrinology. 1996;137:447–54.
64. 64. WY Chen NY Chen J Yun TE Wagner JJ Kopchick 1994 In vitro and in vivo studies of antagonistic effects of human growth hormone analogs J Biol Chem. 269 15892 15897 8195244 1:CAS:528:DyaK2cXkt1Oisrw%3D Chen WY, Chen NY, Yun J, Wagner TE, Kopchick JJ. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. J Biol Chem. 1994;269:15892–7.
65. 65. CJ Ormandy A Camus J Barra D Damotte BK Lucas H Buteau 1997 Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse Genes Dev. 11 167 178 9009200 10.1101/gad.11.2.167 1:CAS:528:DyaK2sXpsVKmsg%3D%3D Ormandy CJ, Camus A, Barra J, Damotte D, Lucas BK, Buteau H, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 1997;11:167–78.
66. 66. Q Shen DD Lantvit Q Lin Y Li K Christov Z Wang 2007 Advanced rat mammary cancers are growth hormone dependent Endocrinology. 148 4536 4544 17584969 10.1210/en.2007-0513 1:CAS:528:DC%2BD2sXhtFWls73P Shen Q, Lantvit DD, Lin Q, Li Y, Christov K, Wang Z, et al. Advanced rat mammary cancers are growth hormone dependent. Endocrinology. 2007;148:4536–44.
67. 67. X Zhang RG Mehta DD Lantvit KT Coschigano JJ Kopchick JE Green 2006 Inhibition of estrogen independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis. 28 143 150 16916863 10.1093/carcin/bgl138 Zhang X, Mehta RG, Lantvit DD, Coschigano KT, Kopchick JJ, Green JE, et al. Inhibition of estrogen independent mammary carcinogenesis by disruption of growth hormone signaling.. Carcinogenesis. 2006;28:143–50.
68. 68. J Divisova I Kuiatse Z Lazard H Weiss F Vreeland DL Hadsell 2006 The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth Breast Cancer Res Treat. 98 315 327 16541323 10.1007/s10549-006-9168-1 1:CAS:528:DC%2BD28XnvVGmu7k%3D Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006;98:315–27.
69. 69. M Llovera C Pichard S Bernichtein S Jeay P Touraine PA Kelly 2000 Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation Oncogene. 19 4695 4705 11032019 10.1038/sj.onc.1203846 1:CAS:528:DC%2BD3cXns1ehsrg%3D Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA, et al. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene. 2000;19:4695–705.
70. 70. S Bernichtein S Jeay R Vaudry PA Kelly V Goffin 2003 New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity Endocrine. 20 177 190 12668884 10.1385/ENDO:20:1-2:177 1:CAS:528:DC%2BD3sXjtFyksLw%3D Bernichtein S, Jeay S, Vaudry R, Kelly PA, Goffin V. New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine. 2003;20:177–90.
71. 71. P Ramamoorthy R Sticca TE Wagner WY Chen 2001 In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells Int J Oncol. 18 25 32 11115535 1:CAS:528:DC%2BD3MXhtlCqtA%3D%3D Ramamoorthy P, Sticca R, Wagner TE, Chen WY. In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. Int J Oncol. 2001;18:25–32.
72. 72. MT Beck SK Peirce WY Chen 2002 Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R Oncogene. 21 5047 5055 12140755 10.1038/sj.onc.1205637 1:CAS:528:DC%2BD38XlsFWrs7k%3D Beck MT, Peirce SK, Chen WY. Regulation of bcl-2 gene expression in human breast cancer cells by prolactin and its antagonist, hPRL-G129R. Oncogene. 2002;21:5047–55.
73. 73. SK Peirce WY Chen 2004 Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice Oncogene. 23 1248 1255 14647416 10.1038/sj.onc.1207245 1:CAS:528:DC%2BD2cXhtlWntbo%3D Peirce SK, Chen WY. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene. 2004;23:1248–55.
74. 74. NY Chen L Holle W Li SK Peirce MT Beck WY Chen 2002 In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R Int J Oncol. 20 813 818 11894130 1:CAS:528:DC%2BD38XislOqsrg%3D Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. Int J Oncol. 2002;20:813–8.
75. 75. S Tomblyn JF Langenheim IC Jacquemart E Holle WY Chen 2005 The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice Int J Oncol. 27 1381 1389 16211235 1:CAS:528:DC%2BD2MXht1amtrbL Tomblyn S, Langenheim JF, Jacquemart IC, Holle E, Chen WY. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. Int J Oncol. 2005;27:1381–9.
76. 76. S Bernichtein JB Jomain PA Kelly V Goffin 2003 The N-terminus of human prolactin modulates its biological properties Mol Cell Endocrinol. 208 11 21 14580717 10.1016/S0303-7207(03)00264-8 1:CAS:528:DC%2BD3sXot1Olt7o%3D Bernichtein S, Jomain JB, Kelly PA, Goffin V. The N-terminus of human prolactin modulates its biological properties. Mol Cell Endocrinol. 2003;208:11–21.
77. 77. U Sivaprasad JM Canfield CL Brooks 2004 Mechanism for ordered receptor binding by human prolactin Biochemistry. 43 13755 13765 15504038 10.1021/bi049333p 1:CAS:528:DC%2BD2cXotlarurk%3D Sivaprasad U, Canfield JM, Brooks CL. Mechanism for ordered receptor binding by human prolactin. Biochemistry. 2004;43:13755–65.
78. 78. A Diogenes AM Patwardhan NA Jeske NB Ruparel V Goffin AN Akopian 2006 Prolactin modulates TRPV1 in female rat trigeminal sensory neurons J Neurosci. 26 8126 8136 16885226 10.1523/JNEUROSCI.0793-06.2006 1:CAS:528:DC%2BD28XosVeiu7k%3D Diogenes A, Patwardhan AM, Jeske NA, Ruparel NB, Goffin V, Akopian AN, et al. Prolactin modulates TRPV1 in female rat trigeminal sensory neurons. J Neurosci. 2006;26:8126–36.
79. 79. FY Ma DR Grattan V Goffin SJ Bunn 2005 Prolactin-regulated tyrosine hydroxylase activity and messenger ribonucleic acid expression in mediobasal hypothalamic cultures: the differential role of specific protein kinases Endocrinology. 146 93 102 15388649 10.1210/en.2004-0800 1:CAS:528:DC%2BD2cXhtFGmt7jJ Ma FY, Grattan DR, Goffin V, Bunn SJ. Prolactin-regulated tyrosine hydroxylase activity and messenger ribonucleic acid expression in mediobasal hypothalamic cultures: the differential role of specific protein kinases. Endocrinology. 2005;146:93–102.
80. 80. A Dagvadorj S collins JB Jomain J Abdulghani J Karras T Zellweger 2007 Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway Endocrinology. 148 3089 3101 17412813 10.1210/en.2006-1761 1:CAS:528:DC%2BD2sXntVOgurs%3D Dagvadorj A, collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology. 2007;148:3089–101.
81. 81. VC Jordan CS Murphy 1990 Endocrine pharmacology of antiestrogens as antitumor agents Endocr Rev. 11 578 610 2292243 1:CAS:528:DyaK3MXlt1Ojt7c%3D Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev. 1990;11:578–610.
82. 82. OM Fischer S Streit S Hart A Ullrich 2003 Beyond Herceptin and Gleevec Curr Opin Chem Biol. 7 490 495 12941424 10.1016/S1367-5931(03)00082-6 1:CAS:528:DC%2BD3sXmslemsrg%3D Fischer OM, Streit S, Hart S, Ullrich A. Beyond Herceptin and Gleevec. Curr Opin Chem Biol. 2003;7:490–5.
83. 83. WY Chen P Ramamoorthy N Chen R Sticca TE Wagner 1999 A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis Clin Cancer Res. 5 3583 3593 10589775 1:CAS:528:DyaK1MXotV2gtr0%3D Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res. 1999;5:3583–93.
84. 84. Scotti ML, Langenheim JF, Tomblyn S, Springs AE, Chen WY. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells. Breast Cancer Res Treat. 2008. doi 10.1007/s10549-007-9789-z.
85. 85. T Yamauchi N Yamauchi K Ueki T Sugiyama H Waki H Miki 2000 Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer J Biol Chem. 275 33937 33944 10938266 10.1074/jbc.M000743200 1:CAS:528:DC%2BD3cXnvVyjtLs%3D Yamauchi T, Yamauchi N, Ueki K, Sugiyama T, Waki H, Miki H, et al. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem. 2000;275:33937–44.
86. 86. G Zhang W Li L Holle N Chen WY Chen 2002 A novel design of targeted endocrine and cytokine therapy for breast cancer Clin Cancer Res. 8 1196 1205 11948133 1:CAS:528:DC%2BD38XjsF2lt7c%3D Zhang G, Li W, Holle L, Chen N, Chen WY. A novel design of targeted endocrine and cytokine therapy for breast cancer. Clin Cancer Res. 2002;8:1196–205.
87. 87. I Garcia-Tunon M Ricote A Ruiz B Fraile R Paniagua M Royuela 2004 Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study Breast Cancer Res. 6 R1 R7 14680494 10.1186/bcr730 1:CAS:528:DC%2BD3sXptVyjtLY%3D Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res. 2004;6:R1–7.
88. 88. MT Beck NY Chen KJ Franek WY Chen 2003 Prolactin antagonist–endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer Cancer Res. 63 3598 3604 12839947 1:CAS:528:DC%2BD3sXltVGrur0%3D Beck MT, Chen NY, Franek KJ, Chen WY. Prolactin antagonist–endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. 2003;63:3598–604.
89. 89. Tomblyn S, Springs AE, Langenheim JF, Chen WY. A multifaceted, targeted combination therapy using three prolactin receptor antagonist based fusion proteins which significantly inhibits tumor recurrence in HER2/neu mice. 89th Meeting of the Endocrine Society Toronto, Canada (june 2–5)[OR-43-1]. 2007, Abstract.
90. 90. V Goffin P Touraine MD Culler PA Kelly 2006 Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab. 2 571 581 17024156 10.1038/ncpendmet0270 1:CAS:528:DC%2BD28XhtFKqtbzP Goffin V, Touraine P, Culler MD, Kelly PA. Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab. 2006;2:571–81.
91. 91. MJ Eijnden van den GJ Strous 2007 Autocrine growth hormone: effects on growth hormone receptor trafficking and signaling Mol Endocrinol. 21 2832 2846 17666586 10.1210/me.2007-0092 1:CAS:528:DC%2BD2sXht1yns77N van den Eijnden MJ, Strous GJ. Autocrine growth hormone: effects on growth hormone receptor trafficking and signaling. Mol Endocrinol. 2007;21:2832–46.
92. 92. SR Oakes FG Robertson JG Kench M Gardiner-Garden MP Wand JE Green 2007 Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions Oncogene. 26 543 553 16862169 10.1038/sj.onc.1209838 1:CAS:528:DC%2BD2sXoslSjtg%3D%3D Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE, et al. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene. 2007;26:543–53.
93. 93. PA Kelly A Bachelot C Kedzia L Hennighausen CJ Ormandy JJ Kopchick 2002 The role of prolactin and growth hormone in mammary gland development Mol Cell Endocrinol. 197 127 131 12431805 10.1016/S0303-7207(02)00286-1 1:CAS:528:DC%2BD38XosFCmsL8%3D Kelly PA, Bachelot A, Kedzia C, Hennighausen L, Ormandy CJ, Kopchick JJ, et al. The role of prolactin and growth hormone in mammary gland development. Mol Cell Endocrinol. 2002;197:127–31.
94. 94. Z Nouhi N Chughtai S Hartley E Cocolakis JJ Lebrun S Ali 2006 Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells Cancer Res. 66 1824 1832 16452244 10.1158/0008-5472.CAN-05-2292 1:CAS:528:DC%2BD28XpsVeksA%3D%3D Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res. 2006;66:1824–32.
95. 95. AS Sultan J Xie MJ LeBaron EL Ealley MT Nevalainen H Rui 2005 Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells Oncogene. 24 746 760 15592524 10.1038/sj.onc.1208203 1:CAS:528:DC%2BD2MXnt1WlsQ%3D%3D Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene. 2005;24:746–60.
96. 96. MT Nevalainen J Xie J Torhorst L Bubendorf P Haas J Kononen 2004 Signal transducer and activator of transcription-5 activation and breast cancer prognosis J Clin Oncol. 22 2053 2060 15169792 10.1200/JCO.2004.11.046 1:CAS:528:DC%2BD2cXpsVWls7o%3D Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol. 2004;22:2053–60.
97. 97. MV Maus SC Reilly CV Clevenger 1999 Prolactin as a chemoattractant for human breast carcinoma Endocrinology. 140 5447 5450 10537179 10.1210/en.140.11.5447 1:CAS:528:DyaK1MXmvFemurk%3D Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology. 1999;140:5447–50.
98. 98. I Gourdou J Paly C Hue-Beauvais L Pessemesse J Clark J Djiane 2004 Expression by transgenesis of a constitutively active mutant form of the prolactin receptor induces premature abnormal development of the mouse mammary gland and lactation failure Biol Reprod. 70 718 728 14613905 10.1095/biolreprod.103.019448 1:CAS:528:DC%2BD2cXhs1ChsLk%3D Gourdou I, Paly J, Hue-Beauvais C, Pessemesse L, Clark J, Djiane J. Expression by transgenesis of a constitutively active mutant form of the prolactin receptor induces premature abnormal development of the mouse mammary gland and lactation failure. Biol Reprod. 2004;70:718–28.
99. 99. C Manhes C Kayser P Bertheau B Kelder JJ Kopchick PA Kelly 2006 Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma J Endocrinol. 190 271 285 16899561 10.1677/joe.1.06829 1:CAS:528:DC%2BD28Xpt1Wjt7g%3D Manhes C, Kayser C, Bertheau P, Kelder B, Kopchick JJ, Kelly PA, et al. Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. J Endocrinol. 2006;190:271–85.